Omnicell logo

Omnicell(NASDAQ) OMCL

Market Cap$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+264%
5 Year-78%
1 Year+12%
1 Month+1%
Premium Feature
Moneyball Superscore
62/100
$35.41
+2.22%
+0.77Today
After hours$35.46+$0.05 (+0.14%)
Omnicell last closing stock price
MetricPriceDate
Last closeUSD 34.642026-10-05
Omnicell stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.27%USD 33.872026-09-28
1 month+0.79%USD 34.372026-09-04
3 month-21.91%USD 44.362026-07-07
Year to date-23.53%USD 45.302025-12-31
1 year+11.92%USD 30.952025-10-03
3 year-19.89%USD 43.242023-10-06
5 year-78.24%USD 159.162021-10-06
Since inception+264.25%USD 9.512001-08-07

Omnicell Financials at a Glance

Market Cap

$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.25B

Net Income (TTM)

$39.08M

EPS (TTM)

$0.85

P/E Ratio

40.96

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$35.41

Volume

632,030.892

Open

$34.95

Previous Close

$35.46

Daily Range

$34.24 - $35.56

52-Week Range

$29.06 - $55.00

Estimated Earnings Date

N/A

OMCL: Motley Fool Moneyball Superscore

62

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Omnicell

**Omnicell, Inc.** makes machines that sort and give out medicine.

These tools help nurses and pharmacists find drugs quickly.

The technology makes hospital work safer and reduces mistakes.

Automated Health and Safety

  • Point of Care: Automated dispensing systems like Titan XT that store medications; represented 56% of total revenues in the six-month period ended June 30, 2026.
  • Service Solutions: Technical support and software as a service, which is software delivered over the internet; accounted for 44% of total revenues in the six-month period ended June 30, 2026.
  • Central Pharmacy: Robotic platforms and carousels used to manage inventory and mix ingredients to create sterile medications given through a vein.
  • Outpatient Services: Tools for specialty pharmacies and a patient engagement platform that help retail pharmacies manage complex drug programs.

Expanding the Digital Pharmacy

  • Introduced XTExtend to provide a console upgrade for existing automated medication cabinets.
  • Expanded specialty pharmacy services to help hospitals manage complex and expensive medication programs.
  • Implemented nearshoring of manufacturing to Mexico to reduce the impact of global trade tariffs.
  • Launched the OmniSphere cloud-based platform to provide data insights across multiple healthcare settings.

Why Efficiency Matters

The company focuses on its vision of the Autonomous Pharmacy, a framework designed to reach zero-error medication management. Most business operations are concentrated in the United States, which accounted for 90% of total revenues in the first half of 2026.

Checking the Pulse

  • Total revenues reached $622.1 million for the six months ended June 30, 2026, up 11% year over year.
  • Gross profit was $293.3 million for the six months ended June 30, 2026, up 23% year over year.
  • Net income for the six-month period ended June 30, 2026, was $35.6 million.
  • Cash and cash equivalents totaled $292.2 million as of June 30, 2026.

The Evolving Pharmacy

Omnicell has transitioned from selling individual pieces of equipment to offering a unified platform for medication management. Its move toward subscription-based services and cloud intelligence helps healthcare providers manage rising costs and labor shortages.

AI Generated • Aug 6, 2026

Industry

Healthcare Equipment and Supplies

Employees

3,580

CEO

Randall A. Lipps

Headquarters

Fort Worth, TX 76137, US

OMCL Financials

Key Financial Metrics (TTM)

Gross Margin

44.77%

Operating Margin

4.73%

Net Income Margin

3.13%

Return on Equity

3.13%

Return on Capital

0.81%

Return on Assets

1.96%

Earnings Yield

2.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

45.61M

Volume

632.03K

Avg. Volume

679.20K

Financials (TTM)

Gross Profit

$558.13M

Operating Income

$58.96M

EBITDA

$106.06M

Operating Cash Flow

$182.67M

Capital Expenditure

-$41.27M

Free Cash Flow

$141.40M

Cash & ST Invst.

$307.01M

Total Debt

$200.00M

Omnicell Performance Analysis

Omnicell annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,295,947,00014.5%
20232023-12-31USD 1,147,112,000-11.5%
20242024-12-31USD 1,112,238,000-3.0%
20252025-12-31USD 1,184,845,0006.5%
Omnicell sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.9%
Q42025-12-311.1%
Q12026-03-31-1.3%
Q22026-06-300.8%
Omnicell annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.12-92.4%
20232023-12-31USD -0.45N/A
20242024-12-31USD 0.27N/A
20252025-12-31USD 0.04-83.6%
Omnicell sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-137.6%
Q12026-03-31654.3%
Q22026-06-30108.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$312.21M

+7.4%

Gross Profit

$152.94M

+19.8%

Gross Margin

48.98%

N/A

Market Cap

$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$453.40K

N/A

Employees

3,485

N/A

Net Income

$24.29M

+330.7%

EBITDA

$13.83M

-57.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$307.01M

-25.4%

Total Debt

$200.00M

-48.0%

Accounts Receivable

$227.05M

-2.4%

Inventory

$96.72M

-8.6%

Long Term Debt

$188.51M

-4.7%

Short Term Debt

$11.49M

-93.8%

Return on Assets

1.96%

N/A

Return on Invested Capital

3.80%

N/A

Free Cash Flow

$60.61M

+95.7%

Operating Cash Flow

$69.55M

+62.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,828.74+0.01%
^DJIDJI
$51,532.64+0.01%
^IXICNASDAQ
$27,658.12+0.01%
BTCBitcoin
$85,726.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$171.92+0.48%
INTCIntel
$112.50-3.18%
NVDANvidia
$239.24+0.14%
NUNu Holdings
$15.66+3.16%

Questions About OMCL

What is the current price of Omnicell?

Omnicell is trading at $35.46 per share.

What is the 52-week range for Omnicell?

Over the past 52 weeks, Omnicell has traded between $29.06 and $55.00.

How much debt does Omnicell have?

As of the most recent reporting period, Omnicell reported total debt of $200.00M.

How much cash does Omnicell have on hand?

Omnicell reported $322.75M in cash and cash equivalents in its most recent financial results.

What is Omnicell’s dividend yield?

Omnicell does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.